EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciriaco, P.
Right arrow Articles by Ricci, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciriaco, P.
Right arrow Articles by Ricci, C.

European Journal of Cardio-Thoracic Surgery, Vol 9, 305-309, Copyright © 1995 by European Association for Cardio-thoracic Surgery


ARTICLES

Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer. Preliminary results

P Ciriaco, EA Rendina, F Venuta, T De Giacomo, G Della Rocca, I Flaishman, C Baroni, E Cortesi, G Bonsignore and C Ricci
Department of Thoracic Surgery, University of Rome La Sapienza, Policlinico Umberto I, Italy.

From January 1991 to November 1993, 110 patients with histologically confirmed stage IIIA and IIIB non-small cell lung cancer (NSCLC), were seen at our Institution. Our study was designed to evaluate whether redirection to surgery of otherwise unresectable patients may be obtained by preoperative therapy. Forty-nine patients were considered eligible for neoadjuvant treatment. Thirty-two (Group I) were treated with two or three cycles of cisplatin, vinblastine and mitomycin C and 17 (Group II) received two cycles of cisplatin, VP16, alpha 1 timosine and interferon. The overall response rate was 81.2% for Group I and 88.7% for Group II. Downstaging was predictive of resectability (P < 0.05). Forty-one patients (83.6%) underwent thoracotomy with 37 (75.5%) radical resections. Conservative techniques (bronchovascular reconstruction) (22 cases) were preferred over pneumonectomy (2 cases). The resectability rate was 84% for Group I and 87% for Group II (P = NS). Treatment-related complications were minor, with no deaths. Postoperative complications occurred in two cases in each group (7.4% and 14.3%). There was no histologic evidence of tumor in three patients. Two-year survival was 75% for Group I and 55% for Group II (P = NS). To date 35 patients who had complete resection are alive, and free of disease. We conclude that preoperative chemotherapy produces high response and resectability rates in both stage IIIA and IIIB unresectable NSCLC; radical resection using a conservative technique is possible in patients who are otherwise unresectable; no local recurrence occurred after radical resection; no significant differences were demonstrated between the two protocols.


This article has been cited by other articles:


Home page
JCOHome page
S. J. Moschos, H. D. Edington, S. R. Land, U. N. Rao, D. Jukic, J. Shipe-Spotloe, and J. M. Kirkwood
Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses
J. Clin. Oncol., July 1, 2006; 24(19): 3164 - 3171.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Sonobe, M. Nakagawa, M. Ichinose, N. Ikegami, M. Nagasawa, and T. Shindo
Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer
Eur. J. Cardiothorac. Surg., November 1, 2000; 18(5): 519 - 523.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts
Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review
Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. A. Rendina, F. Venuta, T. De Giacomo, I. Flaishman, P. Fazi, C. Ricci, Sponsor:, and V. W. Rusch
SAFETY AND EFFICACY OF BRONCHOVASCULAR RECONSTRUCTION AFTER INDUCTION CHEMOTHERAPY FOR LUNG CANCER
J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 830 - 837.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1995 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.